Dekens Eva, Van Damme Eufra, Jashari Ramadan, Van Hoeck Béatrice, François Katrien, Bové Thierry
Department of Cardiac Surgery, University Hospital of Gent, Gent, Belgium.
European Homograft Bank, Cliniques St Jean, Brussels, Belgium.
Interact Cardiovasc Thorac Surg. 2019 Apr 1;28(4):503-509. doi: 10.1093/icvts/ivy316.
Our goal was to evaluate the influence of donor-related factors on the durability of pulmonary homografts (PHGs) for right ventricular outflow tract reconstruction of congenital heart defects.
Between 1990 and 2016, 223 PHGs were used in 197 patients for right ventricular outflow tract reconstruction. Long-term durability was investigated in relation to patient- and disease-specific as well as to donor-related factors, based on the PHG replacement rate. To minimize the effect of outgrowth, a subgroup analysis was performed on patients with PHG size >22 mm, as the discriminant cut-off identified by the classification tree method.
During a median follow-up of 8.5 years [interquartile range (IQR) 12.3], 47 (21%) PHGs were explanted within a mean interval of 9.5 ± 5.3 years, resulting in a freedom from PHG replacement of 82 ± 6% at 10 years. The risk factors for PHG explantation determined by univariable analysis were predominantly patient-related, including younger age (P = 0.003), extra-anatomic implantation (P = 0.006), bicuspidalization (P = 0.002) and younger donor age (P = 0.032). PHG size [hazard ratio (HR) 0.80, 95% confidence interval 0.73-0.88; P < 0.001] was the only independent determinant in multivariable analysis. The subgroup analysis comprised 119 PHG >22 mm, implanted at a median age of 15 years (IQR 7). A significant beneficial effect of ABO matching on the explantation rate was only identified with univariable analysis (HR 0.24, 95% confidence interval 0.12-4.68; P = 0.010).
Cryopreserved PHGs provide a durable substitute for right ventricular outflow tract reconstruction in congenital heart disease. PHG size at the time of implantation remains the principal determinant of PHG explantation during late follow-up. However, once an adult-sized homograft is required, matching for ABO blood group compatibility between host and donor might help to improve homograft durability.
我们的目标是评估供体相关因素对用于先天性心脏缺陷右心室流出道重建的肺同种异体移植物(PHG)耐久性的影响。
1990年至2016年期间,197例患者使用了223个PHG进行右心室流出道重建。基于PHG置换率,研究了与患者和疾病特异性以及供体相关因素相关的长期耐久性。为了尽量减少生长的影响,对PHG尺寸>22 mm的患者进行了亚组分析,这是分类树方法确定的判别临界值。
在中位随访8.5年[四分位间距(IQR)12.3]期间,47个(21%)PHG在平均9.5±5.3年的间隔内被取出,导致10年时无PHG置换的自由度为82±6%。单变量分析确定的PHG取出的危险因素主要与患者相关,包括年龄较小(P = 0.003)、解剖外植入(P = 0.006)、二尖瓣化(P = 0.002)和供体年龄较小(P = 0.032)。PHG尺寸[风险比(HR)0.80,95%置信区间0.73 - 0.88;P < 0.001]是多变量分析中唯一的独立决定因素。亚组分析包括119个PHG>22 mm,植入时的中位年龄为15岁(IQR 7)。仅在单变量分析中确定了ABO血型匹配对取出率有显著有益影响(HR 0.24,95%置信区间0.12 - 4.68;P = 0.010)。
冷冻保存的PHG为先天性心脏病右心室流出道重建提供了一种持久的替代物。植入时的PHG尺寸仍然是晚期随访期间PHG取出的主要决定因素。然而,一旦需要成人尺寸的同种异体移植物,宿主与供体之间ABO血型相容性匹配可能有助于提高同种异体移植物的耐久性。